Medinet Co's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 116.49.
Medinet Co's Days Inventory for the
three
months ended in Mar. 2026 was 50.85.
Medinet Co's Days Payable for the
three
months ended in Mar. 2026 was 33.
Therefore, Medinet Co's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 134.34.
Medinet Co (TSE:2370) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medinet Co Cash Conversion Cycle Related Terms
Medinet Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Medinet Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Medinet Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medinet Co's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medinet Co's Cash Conversion Cycle for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinet Co (TSE:2370) has a Cash Conversion Cycle of 134.34 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medinet Co and its competitors.
Is Medinet Co's Cash Conversion Cycle too high?
Medinet Co's current Cash Conversion Cycle is 134.34. The Biotechnology industry median Cash Conversion Cycle is 103.69. Medinet Co's value of 134.34 is 29.6% above this industry median. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Cash Conversion Cycle compare to VRTX and REGN?
Medinet Co's Cash Conversion Cycle of 134.34 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Medinet Co's value of 134.34 is 29.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinet Co's current Cash Conversion Cycle of 134.34 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medinet Co and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinet Co's current Cash Conversion Cycle is 134.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.74, compared to a current price of 円25.00 — trading 40.1% below its estimated fair value. The current Cash Conversion Cycle is 134.34 and 29.6% above the Biotechnology industry median of 103.69. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Cash Conversion Cycle is 134.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40.1% below its estimated GF Value™ of 円41.74.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
Cash Conversion Cycle: 134.34
GF Value™: 円41.74 vs. price of 円25.00 (40.1% below fair value)
Industry Position: 29.6% above the Biotechnology median
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score
Get the complete analysis for TSE:2370
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
